GSK has announced positive results from a phase 3 trial showing that its RSV vaccine, Arexvy, can be safely and effectively co-administered with the shingles vaccine, Shingrix, in adults aged 50 and older. This offers a convenient option for seniors seeking protection against both respiratory syncytial virus (RSV) and shingles.